# Plain Language Summary: Responsibility in Drug Advertising Act of 2025

This bill would ban pharmaceutical companies from advertising new drugs directly to consumers for the first three years after the drug gets approved by the FDA. Right now, you've probably seen those TV commercials where a drug company advertises a medication directly to patients, listing side effects in fast-talking disclaimers. This bill would stop that practice for newly approved drugs during their first three years on the market. The only exception would be if a drug company asks the FDA for special permission during the third year, and the FDA agrees that advertising would actually benefit public health.

After those first three years, the FDA would still have the power to ban or restrict advertising for any drug that shows serious safety problems. The agency could look at post-approval studies, adverse event reports, and other evidence to decide if a drug's risks are too high to advertise directly to consumers. The bill also tells the FDA to update its advertising rules within a year to make all this work, and it applies to drugs approved roughly one year before the law takes effect and all drugs approved after that.

The practical effect is that patients would see fewer drug commercials for brand-new medications, at least initially. Supporters argue this gives doctors more time to understand how new drugs work in the real world before companies start marketing them directly to patients. Critics might worry that it could delay patients from learning about potentially helpful new treatments. The bill doesn't affect how doctors and pharmaceutical companies communicate with each other, only the ads aimed at regular consumers through TV, social media, and other public channels.

Responsibility in Drug Advertising Act of 2025

DeLauro, Rosa L.

Responsibility in Drug Advertising Act of 2025This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media.&nbsp;Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources.&nbsp;The prohibition applies to new drugs approved beginning one year before the bill’s enactment.